Legend Hony Acquires Stake In Guangzhou Consun Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
Legend Hony, a private investment arm of Legend Holdings, has announced that it will become a minority shareholder of Guangzhou Consun Pharmaceutical with its injection of 180 million yuan into the firm. This is Legend Hony's third foray into the pharmaceutical industry after its investment in Simcere Pharmaceutical Group and buyout of Shijiazhuang Pharmaceutical. Consun is a leading TCM drug maker for kidney diseases. Company officials disclosed that the firm intends to list in the A-share market in the near future, the probability which will be increased by Hony's partnership. The equity investor is consolidating its pharmaceutical resources to maximize its capital value. (Click here for more - Chinese language)
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.